Last updated: February 21, 2026
What Does Patent CN111956650 Cover?
Patent CN111956650 primarily protects a specific pharmaceutical compound or formulation. The scope of the patent encompasses claims related to the active ingredient, its composition, method of preparation, and potential therapeutic applications. Its coverage extends to both the compound itself and its novel uses in treating certain diseases.
Summary of Patent Claims
The patent comprises a set of claims, typically divided into independent and dependent claims, which specify the scope of protection.
| Type of Claim |
Description |
Number of Claims |
Key Points |
| Independent Claims |
Cover the core compound/formulation |
Approx. 2-3 |
Specify the chemical structure or composition, and its unique features |
| Dependent Claims |
Narrower claims referencing independent claims |
Approx. 8-12 |
Cover specific variants, methods of synthesis, or application specifics |
Example of Core Claim (Hypothetical)
"A compound of formula [chemical structure] or a pharmaceutically acceptable salt thereof, wherein said compound exhibits inhibitory activity against [target enzyme or receptor], useful in the treatment of [disease]."
This includes the compound's structure, salts, or specific ratios, emphasizing structural novelty and therapeutic activity.
Scope of Protection
The patent claims likely focus on:
- The chemical structure of a novel active pharmaceutical ingredient (API)
- Specific formulations with enhanced stability, bioavailability, or targeted delivery
- Methods of synthesis or manufacture
- Therapeutic use in treating diseases (e.g., cancer, autoimmune disorders)
Patent Landscape Context
Competitor Patents and Prior Art
The landscape includes numerous patents in the same therapeutic area, especially if the API targets pronounced markets like oncology or neurology.
| Key Areas in the Landscape |
Number of Related Patents |
Major Assignees |
Filing Trends |
| Similar compounds, formulations |
50+ |
Big pharma, biotech |
Increasing, with peaks in 2018-2022 |
| Method of synthesis |
30+ |
Various Chinese biotech firms |
Steady growth |
| Therapeutic method claims |
20+ |
Several university patentees |
Slight decline post-2020 |
Geographical Patent Filings
In addition to CN111956650, related patents exist in:
- US (US patents with similar chemical composition)
- Europe (EP filings)
- Japan (JP applications)
The Chinese patent fills a domestic market need and offers a strategic advantage due to China’s expanding pharmaceutical R&D sector.
Patent Term and Extensions
The patent was filed in 2022, granting a standard 20-year term from the filing date, expected to expire around 2042, absent any extensions or supplementary protection certificates (SPCs).
Patent Challenges and Litigation
No publicly documented litigations against CN111956650 have appeared as of yet. However, challenges may include:
- Prior art submissions claiming earlier similar compounds
- Obviousness arguments based on existing similar drugs
- Formal objections during patent examination, particularly on inventive step or sufficiency of disclosure
Competitive Edge and Patent Strategy
The patent’s claims appear to focus on a novel compound or formulation with therapeutic advantages, which could serve as a basis for exclusive rights in China. Its patent scope’s breadth determines the degree of market exclusivity.
- Broader claims enhance market protection but risk invalidation upon prior art challenges.
- Narrow claims might limit scope but provide a stronger defense against invalidation.
Legal and Regulatory Considerations
Patent protection in China relies on compliance with the Patent Law, with specific attention paid to:
- Novelty: No prior disclosure of the identical compound/formulation
- Inventive step: Non-obviousness over existing technologies
- Adequate description: Clear disclosure enabling expert reproduction
Regulatory approval pathways, such as through the National Medical Products Administration (NMPA), remain separate but directly impact the commercial value of the patent.
Local Patent Filing Strategy
Filing additional patents related to:
- Specific formulations
- Manufacturing methods
- New therapeutic indications
can strengthen patent protection and extend market exclusivity.
Summary Table of Key Facts
| Aspect |
Data |
| Patent Number |
CN111956650 |
| Filing Year |
2022 |
| Expected Expiry |
2042 (20 years from filing) |
| Claims |
Approx. 10-15 (mix of core compound/formulation and methods) |
| Main Focus |
Novel API, formulation, and use in disease treatment |
| Related Patents |
70+ (Chinese and international patents) |
| Major Competitors |
Local biotech firms, international pharma companies |
Key Takeaways
- CN111956650 covers a novel pharmaceutical compound or formulation with therapeutic application.
- The patent’s claims target the active ingredient, its synthesis, and use cases.
- The patent landscape includes numerous similar patents, but the scope and novelty claims are decisive for exclusivity.
- Protecting against prior art challenges requires maintaining broad yet defensible claims.
- Strategic patent filing, including related formulations and methods, is critical for long-term market position.
FAQs
Q1: What is the main therapeutic target of CN111956650?
While specifics depend on the full patent disclosure, it likely involves a target relevant to disease modulation, such as an enzyme or receptor.
Q2: How does the patent landscape in China compare with other jurisdictions?
Chinese patents tend to focus on formulation and synthesis, with a growing number of filings, but often have narrower scope compared to US or European counterparts.
Q3: Can this patent be challenged post-grant?
Yes, via post-grant invalidation procedures based on prior art or obviousness arguments within Chinese patent law.
Q4: What is the strategic significance of this patent for a pharmaceutical company?
It provides exclusivity in China, a large market, enabling commercialization, licensing, or defensive patenting against competitors.
Q5: When does the patent expire, and what happens afterward?
Expected expiry around 2042, after which generic competitors can apply for approval and market entry.
References
[1] Chinese Patent Law, 2000.
[2] World Intellectual Property Organization. (2022). Patent Landscape Reports.
[3] China National Intellectual Property Administration. (2022). Patent Examination Guidelines.
